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Abstract
Background: Early sepsis diagnosis is crucial for the correct management of burn patients, and it clearly influences
outcomes. The systemic inflammatory response triggered by burns mimics sepsis presentation and complicates early
sepsis diagnosis. Biomarkers were advocated to aid the diagnosis of early sepsis. Serum procalcitonin (PCT) exhibits fair
accuracy and good correlation with sepsis severity, being used in diverse clinical settings. However, few studies have
evaluated perioperative changes in PCT levels in burn patients. The present study evaluated PCT kinetics during the
first days after burn injury and subsequent surgical interventions to assess PCT utility in distinguishing septic from non-
septic inflammatory responses.
Methods: This study was a retrospective observational study of all burn patients admitted to the Coimbra Burns Unit
(Portugal) between January 2011 and December 2014 who presented with a total burn surface area ≥ 15% and who
underwent subsequent surgery. PCT kinetics were investigated a) during the first five days after burn injury and b)
preoperatively during the five days after surgery in three subsets of patients, including those with no preoperative and
no postoperative sepsis (NN), no preoperative but postoperative sepsis (NS), and preoperative and postoperative sepsis
(SS). A total of 145 patients met the selection criteria and were included in the analysis.
Results: PCT levels in the first five days after burn injury were significantly higher in patients who developed at least
one sepsis episode (n = 85) compared with patients who did not develop sepsis (n = 60). PCT values > 1.00 ng/mL
were clearly associated with sepsis. Study participants (n = 145) underwent a total of 283 surgical interventions. Their
distribution by preoperative/postoperative sepsis status was 142 (50.2%) in NN; 62 (21.9%) in NS; and 79 (27.9%) in SS.
PCT values exhibited a parallel course in the three groups that peaked on the second postoperative day and returned
to preoperative levels on the third day or later. The lowest PCT values were found in NN, and the highest values were
observed in SS; the NS values were intermediate.
Conclusions: PCT kinetics coupled with a clinical examination may be helpful for sepsis diagnosis during the first days
after burn injury and burn surgery.
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Background
An early diagnosis of sepsis is of the utmost importance
for the correct management of burn patients because it
has a marked impact on treatment outcomes and survival
[1]. Sepsis can lead to multiple organ dysfunction syn-
drome (MODS), which is the cause of most deaths in burn
units [2]. Therefore, a prompt sepsis diagnosis and the
immediate initiation of antimicrobial therapy are needed
to reduce morbidity and mortality. However, the unneces-
sary administration of antimicrobials is often associated
with adverse effects, increased costs and the emergence
and spread of antimicrobial resistance.
It is clinically difficult to identify patients who are
developing sepsis because the overwhelming systemic
inflammatory response triggered by burn trauma mimics
the signs and symptoms of sepsis [3]. A definitive diagno-
sis of sepsis requires microbiological cultures, but the re-
sults are not available for 24 to 48 h, and false negative
results are found in 20–30% of cases. Therefore, the devel-
opment of complementary tools for sepsis diagnosis, such
as the use of biomarkers, is necessary [4].
Biomarkers and their kinetics may aid the clinical
examination in the differentiation of infectious from
non-infectious inflammatory responses [5, 6]. Numerous
sepsis biomarkers are described in the literature [7], and
procalcitonin (PCT) is one of the most studied biomarkers.
PCT exhibits the best discriminative power of all of the bio-
markers that are available at most hospital facilities [8, 9].
Thyroid C cells primarily secrete PCT in healthy subjects,
and it is barely detected in blood (< 0.01 ng/mL). Many
other cell types (liver, kidney, adipocytes, etc.) secrete PCT
in response to direct or indirect infectious stimuli during
septic episodes, and it is massively released into the blood-
stream at concentrations that reach 1000 times its normal
values [10]. Increased PCT is noticeable 2–4 h after sepsis
onset and peaks at 24–48 h. PCT levels decrease by 50%
every 1–1.5 days (half-life) when the infectious process
is controlled [11]. PCT levels are highly correlated with
bloodstream infections [12], and a recent meta-analysis
demonstrated that elevated PCT levels and PCT non-
clearance were related with an increased risk of sepsis
and a higher mortality rate [13]. PCT is accurate for
sepsis diagnosis, and its kinetics exhibit good correlation
with sepsis severity [14]. Therefore, PCT is recommended
in diverse clinical settings, including the exclusion of a
bacterial cause in lower respiratory infections [15] as
well as the diagnosis, stratification, prognosis [16, 17]
and antimicrobial administration guidance in septic
patients [18] and the diagnosis of postoperative infections
[19, 20]. However, the utility of PCT in burn patients
was questioned because of the high rate of false-positive
results from the systemic inflammatory response in-
duced by burn injury and subsequent surgical interven-
tions [21, 22].
The present study evaluated PCT kinetics after a burn
episode and the surgical intervention(s) needed for its
treatment to assess its utility in the differential diagnosis
between septic and non-septic inflammatory responses.
Methods
Study plan
This retrospective observational study used clinical and
laboratory data collected from the health records of all
burn patients admitted to Coimbra Burns Unit (CBU), a
department of Coimbra Hospital and University Centre
(CHUC), a tertiary referral hospital in Portugal, between
January 2011 and December 2014, who presented with a
15% or more total burn surface area (TBSA) and who
underwent subsequent surgery during their hospitalization.
A total of 145 patients met the selection criteria, and their
data were available for analysis.
Sepsis was diagnosed according to the American Burn
Association (ABA) criteria [23]: presence, in at least one
of the initial five days, of a clinical suspicion of infection
coupled with at least three of the following findings:
temperature > 39 °C or < 36.5 °C, tachycardia > 110 beats/
min, tachypnea > 25 breaths/min or minute ventilation >
12 L/min, thrombocytopenia < 100,000/mL, hyperglycaemia
(untreated plasma glucose > 200 mg/dL or intravenous glu-
cose requirement > 7 U/h over 24 h), and enteral feeding
intolerance (abdominal distension or gastric residuals more
than two times feeding rate or diarrhoea > 2500 mL).
Serum PCTconcentrations were measured using TRACE©
(time-resolved amplified cryptate emission) technology
(Kryptor© PCT; Brahms© AG; Hennigsdorf, Germany).
PCT kinetics were evaluated in the first five days after
burn injury in the entire study population, preoperatively
and during the five days after surgery in three subsets of
patients: no preoperative and no postoperative sepsis
(NN), no preoperative but postoperative sepsis (NS), and
preoperative and postoperative sepsis (SS).
Statistical analysis
The maximum value of PCT on each day of the study
was used for statistical analyses.
Qualitative variables (e.g., gender and mortality) are de-
scribed as counts, and quantitative variables (e.g., TBSA
and ABSI - Abbreviated Burn Severity Index: see Additional
file 1) are described as the means and corresponding stand-
ard deviations. The number of surgical interventions
and PCT values by subgroup are described as medians
and interquartile ranges (IQR). Comparisons between
sepsis and no sepsis groups were performed using the
Mann-Whitney test for quantitative variables and the
Fisher’s exact test for qualitative variables. Time compari-
sons of PCT levels were performed using Friedman’s test.
Receiver operating characteristic (ROC) curves and
comparative analysis of the area under the curve (AUC)
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were performed to evaluate the discriminatory power of
PCT levels on consecutive days.
Statistical analysis was performed using SPSS© 23.0
IBM© for Windows©, and a p-value ≤0.05 was consid-
ered significant.
Results
Table 1 presents the primary demographic and baseline
characteristics of the study population, which consisted
of 84 males and 61 females. The sepsis (n = 85) and
non-sepsis (n = 60) groups showed no significant differ-
ences in terms of gender or age, but they were significantly
different in terms of ABSI score, TBSA and mortality.
The analysis of PCT levels during the first five days
after the burn episode showed a statistically significant
difference between the group of patients who developed
at least one sepsis episode during that time and the
group of patients who did not develop sepsis (Fig. 1).
PCT values over 1.00 ng/mL were clearly associated with
septic processes (p < 0.001, Mann-Whiney U test, Table 2).
ROC curves and the AUC were performed to evaluate the
discriminatory power of PCT over consecutive days. These
results demonstrated that the discriminatory power of PCT
levels increased over time (Table 3 and Fig. 2).
All patients (n = 145) underwent at least one surgical
intervention, with a cumulative 283 surgical interven-
tions. Each patient was subjected to a median of three
interventions, with an IQR of [2.00–5.25]. All interven-
tions were performed under general anaesthesia and
were classified as clean-contaminated. The interventions
consisted primarily of escharectomies, skin autografts
and flaps, and digits/limb amputations to a lesser extent.
To assess the influence of surgical trauma on PCT
concentrations, PCT evolution from the day before the
operation (D0) until the fifth postoperative day (D5) was
analysed. Differences in the time evolution of PCT between
the sepsis and non-sepsis groups were statistically sig-
nificant (Table 4), and the discriminatory power in-
creased over time as shown by the ROC curve analysis
(Table 5 and Fig. 3).
Table 1 Study population
Characteristics No Sepsis Sepsis# p-value
Number of patients 85 60
Gender (male/female) 45/40 39/21 0.115
Age (years)$ 56.49 (±18.15) 58.43(±21.89) 0.517
ABSI scorea 7.69 (±2.82) 9.17 (±2.20) 0.000*
TBSA (%)$ 29.97 (±19.94) 34.6 (±17.26) 0.000*
Mortality (No/Yes) 84/1 24/36 0.004*
*p-values < 0.05
$Values are Median (Q1-Q3)
#At least one day with sepsis in the first five days after burn episode
aDescription in Annex I
Fig. 1 Median PCT levels observed in in the first five days after burn injury in septic (Yes) and non-septic (No) patients
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Regarding the preoperative/postoperative sepsis status,
median values had a parallel course in the three groups
(Fig. 4). Values peaked in the second postoperative day
and returned to preoperative levels on the third day or
later. The lowest values were found in the NN group,
which included 142 surgical interventions in patients
without preoperative sepsis and who did not develop
postoperative sepsis through D5 (50.2%). The highest
values were observed in the SS group, which included 62
surgical interventions in patients with pre- and postop-
erative sepsis (21.9%). Group NS exhibited PCT values
roughly in the middle range between the other two
groups and included 79 surgical interventions in patients
who did not exhibit septic processes preoperatively but
developed sepsis on at least one of the five days after
surgery (27.9%). The kinetics of the PCT levels within
each group (Table 3) were significantly different between
days after surgery in the absence (NN) or presence of
sepsis (NS and SS).
Discussion
The present study included a sample of 145 burn patients
from the CBU, and PCT levels were significantly different
between septic and non-septic patients during the first five
days after burn injury. The results indicate that PCT
values evolved in parallel with sepsis development and the
antimicrobial therapy effect. In this important population,
PCT consistently showed good potential to discriminate
between septic and non-septic patients, particularly when
frequent PCT assays were performed and when its kinetics
were dynamically assessed.
To evaluate PCT performance after surgical interventions
and to investigate whether surgical trauma alone could re-
duce the accuracy of the diagnosis of postoperative sepsis,
this study included a substantial and diversified number of
interventions performed in the three subsets of patients
who were organized according to the existence or absence
of preoperative sepsis and the development or worsening of
sepsis after surgery. PCT levels increased modestly and rap-
idly returned to basal levels after the second postoperative
day in patients with no preoperative or postoperative sepsis
episodes. Patients with increased preoperative PCT values
that corresponded to preoperative sepsis exhibited PCT
kinetics with a higher peak on the second postoperative
day, which was presumably related to the additive incre-
ment of PCT of surgical trauma. PCT values returned to
the initial values when antimicrobial therapy was adminis-
tered. PCT levels in patients who only developed sepsis
after surgery exhibited a parallel evolution to the already
septic patients but generally with lower absolute values.
Therefore, PCT is useful for sepsis diagnosis in cases of sur-
gical intervention when preoperative PCT values are known
because PCT kinetics follow the same pattern of evolution
in cases of sepsis as in other critical patients.
The search for sepsis biomarkers is an exciting and
never-ending story [24, 25]. Diverse approaches were used
to identify more precise, practical, quicker, safer and
cheaper chemicals or physical changes that may indicate
the urgent need and adequacy of antimicrobial therapy or
its redundancy to reduce adverse events, microbial resist-
ance and financial costs. Current research is more focused
on molecular (PCR, MALDI-TOF) and/or system-based
(genomics, transcriptomics, proteonomics, metabolomics)
methods for sepsis diagnosis [26–29], but these techniques
are not fully developed, practical or widely available.
An ideal biomarker is not developed, and the use of
PCT as an early distinction between actual septic patients
and patients with merely systemic inflammatory signals
and symptoms during the first days after hospital admis-
sion has been largely discussed in the medical literature in
the last two decades [30–35]. PCT is a useful but not ideal
Table 2 Statistical analysis of PCT kinetics in the first five days after burn injury in septic and non-septic patients
Sepsis Statistic D1 D2 D3 D4 D5 p-value*
No n 64 70 72 69 62
Median [IQR] 0.215 [0.090–0.578] 0.205 [0.09–0.723] 0.210 [0.08–0.668] 0.215 [0.102–0.695] 0.213 [0.118–0.618] 0.557
n 50 53 52 53 52
Yes Median [IQR] 1.085 [0.188–5.440] 1.650 [0.235–4.010] 1.130 [0.335–2.920] 1.060 [0.355–2.927] 0.725 [0.340–2.105] 0.288
p-value** 0.001 0.000 0.000 0.000 0.000
*Friedman test
**Mann-Whiney U test
Table 3 ROC curves for the discriminatory power of PCT levels
between septic and non-septic patients in the first five days
after burn injury
Area Under the Curve (AUROC)
Day Area Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
D1 0.646 0.532 0.759
D2 0.704 0.598 0.810
D3 0.746 0.647 0.845
D4 0.752 0.654 0.850
D5 0.741 0.641 0.841
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biomarker, particularly due to its negative predictive
power [36], which led to its inclusion in algorithms for
sepsis management [37, 38]. The use of serial measure-
ments instead of a single observation reinforces the pre-
dictive power of PCT and reduces the risks of false
negatives and false positives [39–43]. The same consider-
ations are valid for the use of PCT in the investigation of
suspected postoperative sepsis [44], which is currently per-
formed after many types of surgical procedures [45–49].
PCT accuracy in burn patients is controversial [21,
22, 50, 51]. Burn patients are generally excluded from
sepsis studies and clinical trials based on the simplistic
assumption that PCT levels are always elevated in burn
patients as a result of the non-septic inflammatory systemic
response related to burn trauma. However, several studies
consistently demonstrated different PCT kinetics in burn
patients based on the presence or absence of systemic
infection [52–55]. Three recent meta-analysis also vali-
dated the use of PCT for sepsis diagnosis in these patients
[56–58]. PCT evolution is predictable in both cases, and it
provides a reliable means to identify septic processes,
which was first referred to by von Heimburg et al. in 1998
Fig. 2 ROC Curves for the discriminatory power of PCT levels between septic and non-septic patients in the first five days after burn injury
Table 4 Statistical analysis of PCT kinetics from preoperative day (D0) till the fifth postoperative day (D5) for NN, NS and SS groups
Sepsis Statistic D0 D1 D2 D3 D4 D5 p-value*
NN n 212 208 198 186 163 149
Median [IQR] 0.190
[0.110–0.560]
0.200
[0.101–0.615]
0.280
[0.120–0.758]
0.223
[0.118–0.553]
0.195
[0.110–0.430]
0.180
[0.100–0.360]
0.000
NS n 104 103 102 100 87 80
Median [IQR] 0.405
[0.219–0.935]
0.510
[0.240–1.360]
0.640
[0.313–1.590]
0.625
[0.283–1.438]
0.540
[0.260–1.970]
0.515
[0.273–2.045]
0.000
SS n 74 74 74 69 65 62
Median [IQR] 0.653
[0.233–2.193]
0.790
[0.288–2.518]
1.115
[0.413–2.990]
0.880
[0.380–3.115]
0.710
[0.300–1.950]
0.580
[0.248–1.520]
0.000
p-value** 0.000 0.000 0.000 0.000 0.000 0.000
Multiple comparison (p-value***)
(NN,NS) 0.000 0.000 0.000 0.000 0.000 0.000
(NN,SS) 0.000 0.000 0.000 0.000 0.000 0.000
(NS,SS) 0.339 0.225 0.135 0.294 1 1
*Friedman test
**Kruskal Wallis test
***Mann-Whiney U test with Bonferroni correction
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[59]. The immediate inflammatory burst elevates PCT
levels after burn injury, independent of infection, and
grossly correlates with TBSA, but it rarely surpasses
2.0 ng/mL [60, 61]. The maximum PCT value is reached
within 24–48 h in the absence of sepsis and returns to nor-
mal values (1.0–1.5 ng/mL or less) by the end of the third
day. PCT levels continue increasing in the presence of sep-
sis and rapidly reach values greater than 5–100 ng/mL.
PCT levels only diminish with antimicrobial therapy or
terminal immunosuppression, as observed in other forms
of severe trauma [62]. Lavrentieva et al. analysed a sample
of 145 burn patients and found increased PCT levels during
the first 24 h after a burn episode, which subsided in
non-septic patients and continued increasing in septic
patients. These authors demonstrated an inverse
relationship of PCT level tendency with antimicrobial
therapy efficacy. They proposed a cut-off of 1.5 ng/mL
to distinguish between septic and non-septic patients
[63]. Egea-Guerrero et al. [64] and Kim et al. [65] found
the same PCT kinetics and approximate cutoffs.
PCT exhibited a similar kinetics pattern after surgical
intervention [66], but preoperative PCT levels must be
known to use these levels to discriminate between the
postoperative physiological inflammatory response and
postoperative sepsis. Preoperative PCT levels are related
to the presence or absence of an ongoing sepsis process
and possible ongoing antimicrobial therapy, which naturally
influence baseline values [67]. To the best of our know-
ledge, the present study is the first study to specifically
address PCT kinetics after surgical procedures in burn pa-
tients and demonstrate that this biomarker maintains its
performance in this particular set of patients, even in the
presence of preoperative sepsis.
PCT levels coupled with rigorous clinical monitoring
and blood cultures as the diagnostic cornerstone [68] may
help confirm or exclude sepsis in patients during the acute
phase after burn trauma and ascertain the presence of
postoperative sepsis in burn patients. Neither immunode-
pression [69] nor corticotherapy [70] affected the diagnos-
tic performance of PCT, as opposed to other biomarkers,
and PCT also distinguishes contamination from actual
bloodstream infection [71]. The use of PCT dosing may
inclusively reduce healthcare costs and avoid the superflu-
ous use of antimicrobials and consequent increments on
microbial resistance [72, 73].
Table 5 ROC curves for the discriminatory power of PCT levels
between septic and non-septic patients preoperatively and in
the first five days after burn surgery
Area Under the Curve (AUROC)
Day Area Asymptotic 95% Confidence Interval
Lower Bound Upper Bound
D0 0.662 0.591 0.733
D1 0.701 0.633 0.770
D2 0.717 0.649 0.784
D3 0.752 0.686 0.815
D4 0.760 0.696 0.824
D5 0.771 0.708 0.834
Fig. 3 ROC Curves for the discriminatory power of PCT levels between septic and non-septic patients preoperatively and in the first five days
after burn surgery
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The present study also presents some limitations. First,
it was a single-centre, retrospective observational study,
and the results require confirmation using prospective
multicentre trials. Second, the precise influence of anti-
microbial therapy in septic patients could not be evaluated
because of ethical considerations that naturally prevent
antimicrobial denial in face of septic episodes. Third, sub-
group analyses according to the total burned surface area
(TBSA) and the severity of patients’ attainment, for in-
stance, using the Abbreviated Burn Severity Index (ABSI),
was not performed. However, the use of defined and inter-
nationally accepted criteria for the clinical suspicion of
burn sepsis, the homogeneity of therapeutic procedures,
and the use of a standard methodology for the collection,
recording and statistical analysis of the data are clearly
strengths of the present study.
Conclusion
The present study was performed in 145 burn patients
who underwent a high and diversified number of surgi-
cal interventions. The results allow us to conclude that
1) PCT kinetics may aid in the differential diagnosis be-
tween true sepsis and the normal inflammatory response
to burn trauma in the first days after burn injury; and 2)
PCT kinetics may be used to identify postoperative sep-
sis in burn patients who undergo surgical interventions
during their stay in burn units.
Prospective multicentre studies in adult and paediatric
burn patients are needed to confirm these findings and
compare PCT and other biomarkers in these contexts.
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